Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 551

Results For "C"

9223 News Found

Syngene International to acquire stake in O2 Renewable Energy II
News | August 28, 2022

Syngene International to acquire stake in O2 Renewable Energy II

A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power


Moderna files for emergency use of BA.4/BA.5 Omicron booster
Biotech | August 28, 2022

Moderna files for emergency use of BA.4/BA.5 Omicron booster

Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September


Cipla receives 6 observations from USFDA for Goa facility
Drug Approval | August 28, 2022

Cipla receives 6 observations from USFDA for Goa facility

There are no data integrity (DI) observations.


Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles
News | August 27, 2022

Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles

The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive


Benvic acquires specialty U.S. compounder Chemres
News | August 27, 2022

Benvic acquires specialty U.S. compounder Chemres

The ninth acquisition since 2018


Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada
News | August 27, 2022

Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada

With the receipt of the EIR, the inspection stands successfully closed.


Lupin receives UK MHRA Approval of Lutio for treatment of COPD
Drug Approval | August 27, 2022

Lupin receives UK MHRA Approval of Lutio for treatment of COPD

Lutio has the potential to offer significant cost savings when available to UK patients.


Lupin launches Desvenlafaxine extended-release tablets in the US
News | August 27, 2022

Lupin launches Desvenlafaxine extended-release tablets in the US

Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.


Granules India received ANDA approval for Guaifenesin and Pseudoephedrine Hydrochloride ER
Drug Approval | August 27, 2022

Granules India received ANDA approval for Guaifenesin and Pseudoephedrine Hydrochloride ER

Granules now have a total of 51 ANDA approvals from US FDA (49 Final approvals and 2 tentative approvals).


US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad
News | August 26, 2022

US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad

The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.